Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 June 2023 | Story Refiloe Shedile | Photo Supplied
Refiloe Shedile
Refiloe Shedile is an Online Assessment Coordinator in the Centre for Teaching and Learning.

The University of the Free State (UFS) is celebrating Youth Month by showcasing the positive influence of the institution on career development. As part of this initiative, we are sharing the stories of UFS alumni who are now working at the university.

Refiloe Shedile, Online Assessment Coordinator in the Centre for Teaching and Learning (CTL), shares her UFS journey:

 

Q: Year of graduation from the UFS:

A: I completed my undergraduate degree in 2015, followed by my honours degree in 2016.

Q: Qualification obtained from the UFS:

A: My first qualification was a Bachelor of Arts (BA) degree. After that, I pursued a Bachelor of Commerce Honours qualification with specialisation in Industrial Psychology.

Q: Date of joining the UFS as a staff member:

A: I started my journey as a staff member at the UFS through an internship programme in the Centre for Teaching and Learning (CTL) on 1 June 2017.

Q: Initial job title and current job title:

A: My internship focused on technology in teaching and learning, specifically working with assessments on the Questionmark platform. After the internship, I was appointed as an assistant officer in CTL’s Writing Centre (Unit for Language Development); however, I only held this position for four months before there was an opportunity to move back to the division in which I completed my internship. In October 2018, I rejoined the online assessment team as the Questionmark Coordinator and have been working in this role ever since.

Q: How did the UFS prepare you for the professional world?

A: There are numerous initiatives offered by the university that prepared me for the world of work, i.e. the onboarding and new staff orientation sessions conducted by HR; my department also gave me a clear understanding of my individual and team responsibilities, the divisional procedures and culture, and how our work contributed to the larger institutional mission and vision. I was well supported in the team and provided with the necessary resources to excel in my role. Moreover, CTL’s environment enabled me to build strong social connections that continue to be invaluable.

Q: What are your thoughts on transitioning from a UFS alumnus to a staff member?

A: Transitioning from being a UFS alumnus to a staff member was an exciting experience. There was an initial adjustment period to adapt to a nine to five routine; however, I was fortunate enough to join an amazing team led by an inspiring mentor/ line manager. As a Kovsie, you get to develop valuable skills such as optimism, hard work, and resilience; these skills were essential to thrive within the university’s fast-paced environment. Additionally, I believe that being familiar with the UFS environment and culture made it easy for me to better understand and cater for the needs of the students, drawing on my own experiences as a former student. This enabled me to perform my job diligently and effectively.

Q: Any additional comments about your experience?

A: One of my favourite moments about becoming a UFS staff member was the opportunity to work with some of my former lecturers. It was an intriguing experience, being on the other side now, shifting my perspective and seeing them as colleagues rather than just lecturers. This shift in dynamics added a special aspect to my overall experience at the university.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept